Celldex Therapeutics | CLDX - Operating Expenses

Stock Price
29.26
Daily Change
0.72 2.52%
Monthly
27.11%
Yearly
47.18%
Q1 Forecast
28.62

Celldex Therapeutics reported $87.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Celldex Therapeutics USD 87.27M 511.09M Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025